Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

United Therapeutics Corp

UTHR ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: BUY

Last Close

$497.97

▲ +2.12%

Market Cap $21.36B · Vol 203.44K

Key Metrics

P/E Ratio

17.81

FWD: 17.50

Market Cap

$21.36B

Large Cap

Div Yield

N/A

EPS Growth

-5.74%

YoY

RSI (14)

39.97

Momentum

Beta

0.50

vs Market

52W High

$608.63

18.18% below

52W Low

$392.85

26.76% above

Volume

203.44K

Avg 153.92K

P/B

3.00

Price-to-book

ROE

19.71%

Return on equity

Free Float

97.91%

Public shares

Shariah Compliance8 STANDARDS

✗ United Therapeutics Corp (UTHR) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does UTHR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.43%

-7.58%

-8.58%

+4.14%

YTD

+2.20%

+26.19%

+121.19%

+136.54%

Financials & Valuation

TTM · Annual

Total Revenue	$3.18B
Net Income	$1.33B
Revenue Growth (YoY)	-1.92%
Gross Margin	87.92%
Operating Margin	47.67%
Net Profit Margin	41.94%
ROE	19.71%
ROA · ROIC	22.49% · 19.51%

P/E Ratio	17.81
Forward P/E (FY1)	17.50
PEG Ratio	1.34
P/S	7.33
P/B	3.00
P/FCF	22.55
EPS Growth	-5.74%
Outstanding Shares	42.89M

Technical Indicators

50-Day SMA	$524.79
200-Day SMA	$523.56
RSI (14)	39.97
Beta	0.50
52-Week High	$608.63
52-Week Low	$392.85

Volume Today	203.44K
Avg Daily Volume (30D)	153.92K
Relative Volume	1.32x
Volatility (10D)	29.05
Volatility (30D)	25.17
Free Float	97.91%

Analyst Consensus

BUY

Current Price $497.97

Mean Target $652.38

52W Low$392.85 52W High$608.63

Current

Target

$392.85 $608.63

Current Analyst target

+31.01% upside potential · 16 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S8RV10

ISINUS91307C1027

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateOct 27, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.21% JNJ Johnson & Johnson -2.22% ABBV Abbvie Inc -2.99% NVS Novartis AG -13.93% NOVN.S Novartis AG -10.89%

Company Profile

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.